Levocarnitine injection - Lees Pharmaceutical Holdings

Drug Profile

Levocarnitine injection - Lees Pharmaceutical Holdings

Alternative Names: Carnitene

Latest Information Update: 18 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sigma-tau SpA
  • Developer Lees Pharmaceutical Holdings
  • Class Amino acids
  • Mechanism of Action Carnitine acetyltransferase stimulants; Free radical scavengers; Pyruvate dehydrogenase kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic heart failure

Most Recent Events

  • 31 Jan 2011 Phase-II/III clinical trials in Chronic heart failure in China (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top